Cargando…

AV‐1451 tau and β‐amyloid positron emission tomography imaging in dementia with Lewy bodies

OBJECTIVE: Patients with probable dementia with Lewy bodies (DLB) often have Alzheimer's disease (AD)‐related pathology. Our objective was to determine the pattern of positron emission tomography (PET) tau tracer AV‐1451 uptake in patients with probable DLB, compared to AD, and its relationship...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kantarci, Kejal, Lowe, Val J., Boeve, Bradley F., Senjem, Matthew L., Tosakulwong, Nikki, Lesnick, Timothy G., Spychalla, Anthony J., Gunter, Jeffrey L., Fields, Julie A., Graff‐Radford, Jonathan, Ferman, Tanis J., Jones, David T., Murray, Melissa E., Knopman, David S., Jack, Clifford R., Petersen, Ronald C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299616/ https://www.ncbi.nlm.nih.gov/pubmed/27863444 http://dx.doi.org/10.1002/ana.24825

Ejemplares similares

(18)F‐AV‐1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy
por: Nedelska, Zuzana, et al.
Publicado: (2019)

An autoradiographic evaluation of AV-1451 Tau PET in dementia
por: Lowe, Val J., et al.
Publicado: (2016)

Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET
por: Nedelska, Zuzana, et al.
Publicado: (2018)

Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies
por: Chen, Qin, et al.
Publicado: (2022)

Association of Longitudinal β-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia
por: Nedelska, Zuzana, et al.
Publicado: (2019)

β-Amyloid PET and neuropathology in dementia with Lewy bodies
por: Kantarci, Kejal, et al.
Publicado: (2020)

(18)F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies
por: Graff-Radford, Jonathan, et al.
Publicado: (2020)

β-Amyloid PET and (123)I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia
por: Chen, Qin, et al.
Publicado: (2021)

Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment
por: Kantarci, Kejal, et al.
Publicado: (2016)

Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks
por: Schumacher, Julia, et al.
Publicado: (2021)

Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration
por: Kantarci, Kejal, et al.
Publicado: (2022)

FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD
por: Kantarci, Kejal, et al.
Publicado: (2021)

The temporal onset of the core features in dementia with Lewy bodies
por: Choudhury, Parichita, et al.
Publicado: (2021)

(18)F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies
por: Smith, Ruben, et al.
Publicado: (2018)

The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes
por: Jack, Clifford R, et al.
Publicado: (2019)

Rates of lobar atrophy in asymptomatic MAPT mutation carriers
por: Chen, Qin, et al.
Publicado: (2019)

MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous
por: Josephs, Keith A., et al.
Publicado: (2020)

Predicting future rates of tau accumulation on PET
por: Jack, Clifford R, et al.
Publicado: (2020)

[(18)F]-AV-1451 binding in the substantia nigra as a marker of neuromelanin in Lewy body diseases
por: Mak, Elijah, et al.
Publicado: (2021)

Imaging tau burden in dementia with Lewy bodies using [(18)F]-AV1451 positron emission tomography
por: Mak, Elijah, et al.
Publicado: (2021)

TREM2 p.R47H substitution is not associated with dementia with Lewy bodies
por: Walton, Ronald L., et al.
Publicado: (2016)

Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology
por: Savica, Rodolfo, et al.
Publicado: (2016)

In vivo retention of (18)F-AV-1451 in corticobasal syndrome
por: Smith, Ruben, et al.
Publicado: (2017)

Increased Uptake of AV-1451 in a Subacute Infarction Lesion
por: Cho, Soo Hyun, et al.
Publicado: (2018)

Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition
por: Kantarci, Kejal, et al.
Publicado: (2016)

Mitochondrial genomic variation in dementia with Lewy bodies: association with disease risk and neuropathological measures
por: Valentino, Rebecca R., et al.
Publicado: (2022)

An updated radiosynthesis of [(18)F]AV1451 for tau PET imaging
por: Mossine, Andrew V., et al.
Publicado: (2017)

Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging
por: Vemuri, Prashanthi, et al.
Publicado: (2018)

(18)F-FDG PET-CT pattern in idiopathic normal pressure hydrocephalus
por: Townley, Ryan A., et al.
Publicado: (2018)

Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenoconversion in Mapt Mutation Carriers
por: Chen, Qin, et al.
Publicado: (2019)

(18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes
por: Tsai, Richard M., et al.
Publicado: (2019)

Quantification of Tau Load Using [(18)F]AV1451 PET
por: Golla, Sandeep S. V., et al.
Publicado: (2017)

The Role of 18F-Flortaucipir (AV-1451) in the Diagnosis of Neurodegenerative Disorders
por: Roy, Saswata, et al.
Publicado: (2021)

White Matter Degeneration Pathways Associated With Tau Deposition in Alzheimer Disease
por: Tian, Jianqiao, et al.
Publicado: (2023)

Abnormal daytime sleepiness in dementia with Lewy bodies compared to Alzheimer’s disease using the Multiple Sleep Latency Test
por: Ferman, Tanis J, et al.
Publicado: (2014)

Clinicopathological and (123)I‐FP‐CIT SPECT correlations in patients with dementia
por: Jung, Youngsin, et al.
Publicado: (2018)

Increased retention of tau PET ligand [(18)F]-AV1451 in Alzheimer’s Disease Psychosis
por: Gomar, J. J., et al.
Publicado: (2022)

(18)F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy
por: Passamonti, Luca, et al.
Publicado: (2017)

Associations of quantitative susceptibility mapping with Alzheimer’s disease clinical and imaging markers
por: Cogswell, Petrice M., et al.
Publicado: (2020)

Considerations and code for partial volume correcting [(18)F]-AV-1451 tau PET data
por: Baker, Suzanne L., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ulqqk8te94160f9t78k3bbicp5